Who is sponsoring NCT04129996?

NCT04129996 is sponsored by Fudan University.

What drugs are being tested in NCT04129996?

Interventions in NCT04129996: camrelizumab in combination with nab-paclitaxel and famitinib.

What condition does NCT04129996 study?

NCT04129996 studies Triple-Negative Breast Cancer.

Is NCT04129996 still recruiting?

NCT04129996 is currently status unknown. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT04129996

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Status unknown Phase 2 Last updated 11 January 2022

What this trial tests

Phase 2 trial testing camrelizumab in combination with nab-paclitaxel and famitinib in Triple-Negative Breast Cancer in 46 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
1 September 2022

1 September 2022

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	1 October 2019
Primary completion	1 September 2022
Estimated completion	1 September 2022
Sites	1 location across China

Drugs / interventions tested

camrelizumab in combination with nab-paclitaxel and famitinib — full drug profile →

Conditions studied

Triple-Negative Breast Cancer — all drugs for Triple-Negative Breast Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 70, female only, with Triple-Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is being conducted to evaluate the efficacy, safety of camrelizumab in combination with nab-paclitaxel and famitinib in Patients with unresectable locally advanced or metastatic immunomodulatory triple negative breast Cancer..

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.
Marra A, Trapani D, Viale G, Criscitiello C, et al · · 2020 · cited 209× · PMID 33088912 · DOI 10.1038/s41523-020-00197-2
Advances in immunotherapy for triple-negative breast cancer.
Liu Y, Hu Y, Xue J, Li J, et al · · 2023 · cited 198× · PMID 37660039 · DOI 10.1186/s12943-023-01850-7
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, et al · · 2024 · cited 133× · PMID 39138146 · DOI 10.1038/s41392-024-01899-w
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, et al · · 2022 · cited 81× · PMID 35247906 · DOI 10.1158/1078-0432.ccr-21-4313
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
Wu SY, Xu Y, Chen L, Fan L, et al · · 2022 · cited 69× · PMID 35337339 · DOI 10.1186/s12943-022-01536-6
Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis.
Fernández-Nogueira P, Fuster G, Gutierrez-Uzquiza Á, Gascón P, et al · · 2021 · cited 43× · PMID 34201840 · DOI 10.3390/cancers13133146
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.
Imani S, Farghadani R, Roozitalab G, Maghsoudloo M, et al · · 2025 · cited 41× · PMID 40281554 · DOI 10.1186/s13046-025-03394-8
Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer.
Zhao S, Chen DP, Fu T, Yang JC, et al · · 2023 · cited 39× · PMID 37880211 · DOI 10.1038/s41467-023-42504-y

Verify or expand the search:

Other recruiting trials for Triple-Negative Breast Cancer

Currently open trials in the same condition.

NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Pa · NA · recruiting
NCT07104266 — Triple Negative Breast Cancer and Celecoxib. Pilot Study · Phase 2 · recruiting
NCT06393374 — Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · Phase 3 · recruiting
NCT05806060 — Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer · Phase 3 · recruiting
NCT05760378 — Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or M · Phase 3 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04129996 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04129996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing